{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:48:29Z","timestamp":1790754509312,"version":"4.1.0"},"reference-count":58,"publisher":"Japan Atherosclerosis Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.5551\/jat.rv17030","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T17:29:30Z","timestamp":1547832570000},"page":"207-215","source":"Crossref","is-referenced-by-count":87,"title":["Diagnosis and Management of Statin Intolerance"],"prefix":"10.5551","volume":"26","author":[{"given":"Rodrigo","family":"Alonso","sequence":"first","affiliation":[{"name":"Department of Nutrition, Clinica Las Condes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Cuevas","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Clinica Las Condes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cafferata","sequence":"additional","affiliation":[{"name":"Cardiovacular Prevention Department. Sanatorio Finochietto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A, Cooney MT, Corr\u00e0 U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, L\u00f8chen ML, L\u00f6llgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J, 2016; 37: 2315-2381","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"2","unstructured":"2) Scandinavian Simvastatin Survival Group. Randomised<b> <\/b>Trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 1994; 344: 1383-1389"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med, 1998; 129: 681-689","DOI":"10.7326\/0003-4819-129-9-199811010-00002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004; 363: 757-767","DOI":"10.1016\/S0140-6736(04)15690-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435","DOI":"10.1056\/NEJMoa050461"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207","DOI":"10.1056\/NEJMoa0807646"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Gislason GH, Rasmussen JN, Abildstr\u00f8m SZ, Gadsb\u00f8ll N, Buch P, Friberg J, Rasmussen S, K\u00f8ber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J, 2006; 27: 1153-1158","DOI":"10.1093\/eurheartj\/ehi705"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med, 2004; 19: 638-645","DOI":"10.1111\/j.1525-1497.2004.30516.x"},{"key":"10","unstructured":"10) Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk W. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol, 2005; 21: 485-488"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Guglielmi V, Bellia A, Pecchioli S, Della-Morte D, Parretti D, Cricelli I, Medea G, Sbraccia P, Lauro D, Cricelli C, Lapi F. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis, 2017; 263: 36-41","DOI":"10.1016\/j.atherosclerosis.2017.05.018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Boklage S, Malangone-Monaco E, Lopez-Gonzalez L, Ding Y, Henriques C, Elassal J. Statin utilization patterns and outcomes for patients with acute coronary s\u00edndrome during and following inpatients admissions. Cardiovasc Drugs Ther, 2018; 32: 273-280","DOI":"10.1007\/s10557-018-6800-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Colantonio L, Huang L, Monda KL, Bittner MC, Taylor TM, Glasser SP, Muntner P, Rosenson RS. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol, 2017; 2: 890-895","DOI":"10.1001\/jamacardio.2017.0911"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) De Vera M, Bhole V,Burns L, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol, 2014; 78: 684-698","DOI":"10.1111\/bcp.12339"},{"key":"15","unstructured":"15) Bijlsma M, Vansteelandt S, Janssen F, Hak E. The effect of adherence to statin therapy on cardiovascular mortality: quantification of unmeasured bias using falsification endpoints. BMC Public Health, 2016; 16: 303. doi: 10.1186\/s12889-016-2986-2990"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Haukka J, Niskanen L, Partonen T, L\u00f6nnqvist J, Thihonen J. Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Saf, 2012; 21: 61-69","DOI":"10.1002\/pds.2255"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des, 2011; 17: 3669- 3689","DOI":"10.2174\/138161211798220891"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J, 2016; 37: 908-916","DOI":"10.1093\/eurheartj\/ehv641"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Stulc T, Ceska R, Gotto Jr A. Statin intolerance: The clinician\u2019s perspective. Curr Atheroscler Rep, 2015; 17: 69. Doi: 10.1007\/s11883-015-0552-3","DOI":"10.1007\/s11883-015-0552-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol, 2014; 8: S72-S81","DOI":"10.1016\/j.jacl.2014.03.002"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Wai MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol, 2013; 7: 472-484","DOI":"10.1016\/j.jacl.2013.03.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci, 2015; 11: 1-23","DOI":"10.5114\/aoms.2015.49807"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Plan\u00e8s S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect, 2016; 4: e00208","DOI":"10.1002\/prp2.208"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ce\u0161ka R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with musclerelated statin intolerance: the GAUSS-3 randomized clinical trial. JAMA, 2016; 315: 1580-1590","DOI":"10.1001\/jama.2016.3608"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poluter N, Collins R, Seveer P; ASCOR investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet, 2017; 389: 2473-2481","DOI":"10.1016\/S0140-6736(17)31075-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27) Sposito A, Rocha Faria J, de Carvalho L, Lorenzatti A, Cafferata A, Elikir G, Esteban E, Morales Villegas EC, Bodanese LC, Alonso R, Ruiz AJ, Rocha VZ, Faludi AA, Xavier HT, Coelho OR, Assad MH, Izar MC, Santos RD, Fonseca FA, Mello E Silva A, Silva PM, Bertolami MC; on behalf of the Luso-Latin American Consortium on Statin-Associated Muscle Symptoms. Statin-associated muscle symptoms: position paper from the Luso-Latin America Consortium. Curr Med Res Opin, 2017; 33: 239-251","DOI":"10.1080\/03007995.2016.1252740"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28) Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 2016; 388: 2532-2561","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29) Ganga HV, Slim HB, Thomnpson PD. A systematic review of statin-induced muscle problems in clinical trial. Am Heart J, 2014; 168: 6-15","DOI":"10.1016\/j.ahj.2014.03.019"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30) Serban MC, Colantonio L, Manthripragada A, Monda K, Bittner V, Banach M, Chen L, Huang L, Dent R, Kent ST, Muntner P, Rosenson RS. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. JACC, 2017; 69: 1386-1395","DOI":"10.1016\/j.jacc.2016.12.036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31) Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadellus M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Therapeut, 2014; 96: 470-476","DOI":"10.1038\/clpt.2014.121"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32) Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther, 2005; 19: 403-414","DOI":"10.1007\/s10557-005-5686-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33) Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol, 2014; 8: S58-S71","DOI":"10.1016\/j.jacl.2014.03.004"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34) Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation, 2013; 127: 96-103","DOI":"10.1161\/CIRCULATIONAHA.112.136101"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35) Sinzinger H, O\u2019Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol, 2004; 57: 525-528","DOI":"10.1111\/j.1365-2125.2003.02044.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36) Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, D\u2019Hemecourt PA, Thompson PD. Effect of statins on creatin kinase levels before and after a marathon run. Am J Cardiol, 2012; 109: 282-287","DOI":"10.1016\/j.amjcard.2011.08.045"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37) Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med, 2012; 172: 1180-1182","DOI":"10.1001\/archinternmed.2012.2171"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38) Arambepola C, Farmer AJ, Perera R, Neils HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis, 2007; 195: 339-347","DOI":"10.1016\/j.atherosclerosis.2006.09.030"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39) Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA. A systematic review and metaanalysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2007; 27: 1803-1810","DOI":"10.1161\/ATVBAHA.107.145151"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40) Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E. Statins for children with familial hypercholesterolemia. Cochrane Database Syst<b> <\/b>Rev, 2017; doi:10.1002\/14651858","DOI":"10.1002\/14651858"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41) Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. J Clin Lipidol, 2016; 10: 1153-1162","DOI":"10.1016\/j.jacl.2016.05.010"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42) Braamskamp MJ, Kusters DM, Avis HJ, Smets EM, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA. Longterm treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. Pediatr Drugs, 2015; 17: 159-166","DOI":"10.1007\/s40272-014-0116-y"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43) Humphries S, Cooper J, Dale P, Ramaswami U, FH Paediatric Register Steering Group. The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data. J Clin Lipidol, 2018; 12: 25-32","DOI":"10.1016\/j.jacl.2017.11.005"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44) Saltijeral A, P\u00e9rez de Isla L, Alonso R, Mu\u00f1iz O, D\u00edaz-D\u00edaz JL, Fuentes F, Mata N, de Andr\u00e9s R, D\u00edaz-Soto G, Pastor J, Pinilla JM, Zamb\u00f3n D, Pinto X, Badim\u00f3n L, Mata P; SAFEHEART Investigators. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. Rev Esp Cardiol, 2017; 70: 444-450","DOI":"10.1016\/j.recesp.2016.10.012"},{"key":"44","doi-asserted-by":"crossref","unstructured":"46) Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, Moriarty PM. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother, 2008; 42: 341-346","DOI":"10.1345\/aph.1K604"},{"key":"45","doi-asserted-by":"crossref","unstructured":"47) Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week ro- suvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol, 2009; 103: 393-394","DOI":"10.1016\/j.amjcard.2008.09.095"},{"key":"46","doi-asserted-by":"crossref","unstructured":"48) Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol, 2008; 101: 1747-1748","DOI":"10.1016\/j.amjcard.2008.02.061"},{"key":"47","doi-asserted-by":"crossref","unstructured":"49) Jacobson T, Khan A, Maki K, Brinton E, Cohen J. Provider recommendations for patients-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. J Clin Lipidol, 2018; 12: 78-88","DOI":"10.1016\/j.jacl.2017.09.006"},{"key":"48","unstructured":"50) Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du , Pordy R, Gipe DA, ODYSSEY ALTERNATIVE. efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 monoclonal antibody, alirocu- mab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin arm. Circulation, 2014; 130: 2108-2109"},{"key":"49","doi-asserted-by":"crossref","unstructured":"51) Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M; GAUSS-2 investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol, 2014; 63: 2541-2548","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"50","doi-asserted-by":"crossref","unstructured":"52) Ballantyne C, Banach M, Mancini J, Lepor N, Hanselman J, Zhao X, Leiter L. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patient with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, 2018; 277: 195-203","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"51","doi-asserted-by":"crossref","unstructured":"53) Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, Cohen JD. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol, 2016; 10: 833-841","DOI":"10.1016\/j.jacl.2016.02.016"},{"key":"52","doi-asserted-by":"crossref","unstructured":"54) Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults. J Gerontol A Biol Sci Med Sci, 2017; 62: 879-887","DOI":"10.1093\/gerona\/62.8.879"},{"key":"53","unstructured":"55) Millan J, Pedro-Botet J, Climent E, Rius J, Statin Associated myopathy in clinical practice. Results of DAMA study. Clin Investig Arterioscler, 2017; 29: 7-12"},{"key":"54","doi-asserted-by":"crossref","unstructured":"56) Brinton EA, Maki KC, Jacobson TA, Sponseller CA, Cohen JD. Metabolic syndrome is associated with muscle symptoms among statin users. J Clin Lipidol, 2016; 10: 1022-1029","DOI":"10.1016\/j.jacl.2016.05.003"},{"key":"55","doi-asserted-by":"crossref","unstructured":"57) Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Kees Hovigh G, Farnier M, Moriarty PM, Bittner VA, Lip GY, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol, 2015; 178: 111-116","DOI":"10.1016\/j.ijcard.2014.10.118"},{"key":"56","doi-asserted-by":"crossref","unstructured":"58) Robinson CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, Anderson JL. Hypothyrodism as a risk factor for statin intolerance. J Clin Lipidol, 2014; 8: 401-407","DOI":"10.1016\/j.jacl.2014.05.005"},{"key":"57","doi-asserted-by":"crossref","unstructured":"59) Palmer S, Craig J, Navaneethan S, Tonelli M, Pellegrini F, Strippoli G. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med, 2012; 157: 263-275","DOI":"10.7326\/0003-4819-157-4-201208210-00007"},{"key":"58","doi-asserted-by":"crossref","unstructured":"60) Kinoshita M, Yokote K, Ara, H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, HAmaguchi H, Hara M, Hirot T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yocode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for Epidemiology and Clinical Managelemt of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/3\/26_RV17030\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:32:24Z","timestamp":1551486744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/26\/3\/26_RV17030\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17030","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}